BiotechTube

Xuezhikang Capsule + Atorvastatin Calcium Tablets

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Metabolism Disorder, Lipid

Conditions

Metabolism Disorder, Lipid, Metabolism Disorder, Glucose

Trial Timeline

Aug 2, 2022 → Apr 2, 2024

NCT ID
NCT05238012

About Xuezhikang Capsule + Atorvastatin Calcium Tablets

Xuezhikang Capsule + Atorvastatin Calcium Tablets is a approved stage product being developed by AstraZeneca for Metabolism Disorder, Lipid. The current trial status is completed. This product is registered under clinical trial identifier NCT05238012. Target conditions include Metabolism Disorder, Lipid, Metabolism Disorder, Glucose.

What happened to similar drugs?

4 of 19 similar drugs in Metabolism Disorder, Lipid were approved

Approved (4) Terminated (2) Active (15)
✅cyclosporine micro-emulsionNovartisApproved
✅Fluvastatin sodiumNovartisApproved
🔄liraglutide + placebo + liraglutide + placeboNovo NordiskPhase 3
🔄liraglutide + placeboNovo NordiskPhase 3
🔄Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3
🔄Semaglutide + Placebo (semaglutide)Novo NordiskPhase 3
🔄Semaglutide + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05238012ApprovedCompleted

Competing Products

20 competing products in Metabolism Disorder, Lipid

See all competitors
ProductCompanyStageHype Score
mRNA-3704ModernaPhase 2
0
E2609EisaiPhase 1
29
E2006EisaiPhase 1
29
AZD3480 + Placebo + Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)AstraZenecaPhase 1
29
Rabeprazole or Esomeprazole or LanzoprazoleAstraZenecaPre-clinical
26
cyclosporine micro-emulsionNovartisApproved
35
Fluvastatin sodiumNovartisApproved
43
NNC0165-1562 + placeboNovo NordiskPhase 1
29
liraglutideNovo NordiskPhase 1
29
NNC9204-0530 + placeboNovo NordiskPhase 1
29
liraglutide + placeboNovo NordiskPhase 1
29
liraglutide + placebo + liraglutide + placeboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40
Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3
40
Semaglutide + Placebo (semaglutide)Novo NordiskPhase 3
40
liraglutide + orlistat + placeboNovo NordiskPhase 2
35
NNC 0070-0002-0453 + '2-0453 + placeboNovo NordiskPhase 1
21
NNC0194-0499 + PlaceboNovo NordiskPhase 1
29
Semaglutide + PlaceboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40